Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications

• Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension
• HYPER-H21-4 will build on successes witnessed in initial human hypertension studies
• The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease
• Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology

With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience LEXX, a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of orally-delivered fat-soluble active pharmaceutical ingredients (“APIs”) through its patented DehydraTECH(TM) drug delivery technology is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors.

In January 2022, Lexaria expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies, HYPER-H21-1 and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer

Do you have a questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.HempWire.com
303.498.7722 Office
Editor@HempWire.net

HempWire is part of the InvestorBrandNetwork.

Image Sourced from Pixabay